9 edition of Filgrastim (r-metHuG-CSF) in Clinical Practice found in the catalog.
May 13, 1998
by Informa Healthcare
Written in English
|The Physical Object|
|Number of Pages||673|
COVID Resources. Reliable information about the coronavirus (COVID) is available from the World Health Organization (current situation, international travel).Numerous and frequently-updated resource results are available from this ’s WebJunction has pulled together information and resources to assist library staff as they consider how to handle . The recommended starting dose is MU/kg/day (5 μg/kg/day) as a single dose or in divided doses. Dose adjustment. Filgrastim should be administered daily by subcutaneous injection until the neutrophil count has reached and can be maintained at more than x 10 9 /l. When the response has been obtained, the minimal effective dose to Neutrophil count: Filgrastim dose adjustment.
Filgrastim works by boosting production of infection-fighting white cells in the bone marrow. A well-known side effect of cancer treatment is Author: Elaine Schattner. Filgrastim is a glycoprotein that binds to and stimulates neutrophils to divide and differentiate. Also activates mature neutrophils. Binding to a polyethylene glycol molecule prolongs its effects. Therapeutic Effects: Decreased incidence of infection in patients who are neutropenic from chemotherapy. + +.
Filgrastim, a hematopoietic agent, decreases the risk of infection in patients suffering from cancer during also raises the number of stem cells in the body and treats low white blood cell counts. Filgrastim (NEUPOGEN®) is the originator recombinant human granulocyte colony-stimulating factor widely used for preventing neutropenia-related infections and mobilizing hematopoietic stem cells. This report presents findings of a systematic literature review and meta-analysis of efficacy and safety of originator filgrastim to update previous by:
Third United Nations Conference on the Law of the Sea
Evolution, genetics and social behavior
Submission of the United Steelworkers of America to the standing committee on resources development regarding
The 2000 Import and Export Market for Coal, Coke, and Briquettes in Mozambique (World Trade Report)
U.S. relations with Korea
Standing Advisory Council on Religious Education
measure for magistrates.
stratigraphy and petrogenesis of the Grand Ronde basalt in the lower Salmon and adjacent Snake River canyons
A Bill to Alter and Establish Certain Post Roads
The people and politics of Latin America
Trade associations in the distributive trades
Duo [for] trumpet & percussion
The problem of suffering in the Old Testament.
Annals of the Honorable East-India Company
imperial factor in South Africa
Use filgrastim injection as ordered by your doctor. Read all information given to you. Follow all instructions closely. It is given as a shot into the fatty part of the skin. It may be given into a vein by a doctor or other healthcare provider. Keep taking filgrastim injection as you have been told by your doctor or other health care provider 9/ 26 rows (filgrastim-aafi) July Neupogen (filgrastim) Nivestym Information: Fulphila.
A glycoprotein, filgrastim binds to and stimulates immature neutrophils to divide and differentiate. Also activates mature neutrophils. Therapeutic Effects: Decreased incidence of infection in patients who are neutropenic from chemotherapy or other causes.
Improved harvest of progenitor cells for bone marrow transplantation. + +. Name /bks__deglins_md_disk/filgrastim 02/12/ PM Plate # 0-Composite pg 1 # 1 PDF Page #1 Canadian drug name. Genetic Size: KB. In Summary.
Commonly reported side effects of filgrastim include: hyperuricemia, increased lactate dehydrogenase, increased leukocyte alkaline phosphatase, increased serum alkaline phosphatase, ostealgia, and side effects include: arthralgia, headache, myalgia, and pruritus.
See below for a comprehensive list of adverse effects.9/ Providing a wealth of insights Filgrastim book from the experience of groundbreaking researchers working in the field, this Second Edition of a landmark volume brings preclinical and clinical studies of Filgrastim (r-metHuG-CSF) up to date with completely revised and expanded discussions of its biology, biochemistry, structure, pharmacology, clinical applications, and by: filgrastim is a topic covered in the Davis's Drug Guide.
To view the entire topic, please sign in or purchase a subscription. Nursing Central is an award-winning, complete mobile solution for nurses and students.
Look up information on diseases, tests, and procedures; then consult the database with 5,+ drugs or refer to 65,+ dictionary terms.
FILGRASTIM: MCG/ML: SYRINGE: Prescription: None No: No: Approval Date(s) and History, Letters, Labels, Reviews for BLA Original Approvals or Tentative Approvals.
Action Date Submission Action Type Submission Classification Review Priority; Orphan Status Letters, Reviews, Labels, Patient Package Insert Notes Url. Pegfilgrastim has a longer half-life than filgrastim, particularly after the administration of chemotherapy. Because pegfilgrastim is cleared by neutrophils and their precursors, its half-life is prolonged by chemotherapy, and in this setting the drug is “self-regulating,” with levels persisting through the postchemotherapy nadir and.
Filgrastim in Clinical Practice by George Morstyn, T. Michael Dexter, MaryAnn Foote | Editorial Reviews. Filgrastim as treatment or prophylaxis for decreasing infectious episodes, intensifying immunosuppresive therapy, and mobilizing progenitor stem cells In this second edition of the book, each chapter has been revised and Author: George Morstyn.
Action Date Submission Supplement Categories or Approval Type Letters, Reviews, Labels, Patient Package Insert Note Url; 08/01/ SUPPL Labeling-Package Insert. FDA approves Neupogen for treatment of patients with radiation-induced myelosuppression following a radiological/nuclear incident.
On MaFDA approved use of. Proper Use. Drug information provided by: IBM Micromedex A nurse or other trained health professional may give you this medicine. It is given as a shot under your skin or into a vein. Purple Book: Database of Licensed Biological Products. Advanced Search.
Enter data into one or more fields below. Click the View All Database Entries to view all products in the database. Purple Book database last updated on: March 9th, Search. Reset. Additional Search Filters. Filgrastim is also approved to help move stem cells from the bone marrow to the bloodstream so that they can be collected, stored, and then given back to the patient in autologous stem cell transplantation.
Filgrastim is also approved to treat neutropenia. Filgrastim is a biological medicine. Biological medicines must be prescribed and dispensed by brand name, see Biological medicines and Biosimilar medicines, under Guidance on prescribing.
1 million units of filgrastim solution for injection contains 10 micrograms filgrastim. Filgrastim was first discovered by Amgen, Inc.
and sold under the brand name Neupogen. Large number of biosimilar companies are engaged in the manufacture and marketing of Filgrastim across the world. Filgrastim costs around US$ in the U.S, around GBP 50 in the U.K., and US$ in developing countries/5(21).
Side Effects. Drug information provided by: IBM Micromedex Along with its needed effects, a medicine may cause some unwanted effects.
Although not all of these side effects may occur, if they do occur they may need medical attention. ISBN: OCLC Number: Description: xv, pages: illustrations ; 24 cm: Contents: The Biology, Biochemistry, and Pharmacology of G-CSF Biology of G-CSF, Graham Molineux and T. Michael DexterBiochemistry and Structure of Filgrastim (r-metHuG-CSF), Timothy Osslund and Thomas C.
BoonePharmacology of Filgrastim (r. Takashi Kato, in Handbook of Hormones, Use for Diagnosis and Treatment. Recombinant G-CSF therapies by filgrastim and lenograstim have been established in several indications [14,15].Primarily, G-CSF is administered to patients with severe congenital or chronic neutropenia caused by a myeloid maturation arrest in the bone marrow .G-CSF is also applicable to.
Pegfilgrastim is approved to reduce the chance of infection in patients with: Neutropenia caused by myelosuppressive chemotherapy for certain types of cancer. Pegfilgastrim is a form of filgrastim that has polyethylene glycol (PEG) attached to it.
This form stays in the body longer than does filgrastim, so it doesn’t need to be given as often.The FDA approved filgrastim-sndz (Zarxio, Sandoz, Inc.), the first biosimilar product available in the United States, in March Zarxio has the same mechanism of action, route of administration, strength, and dosage form as Amgen’s Neupogen.
9Cited by: 3. Filgrastim, a recombinant human granulocyte colony-stimulating factor (G-CSF), has identical biological activity to that of endogenous human G-CSF, but differs in that it contains an N-terminal methionine residue and is not glycosylated.
It principally stimulates activation, proliferation and differentiation of neutrophil progenitor cells and has been evaluated in the Author: D. Dunlop, K. Eguchi, Thoracic Oncology, R. Haas, Y. Itoh, E. Masson, R. Pettengell.